Börzsönyi M, Torok G, Pinter A, Surján A, Csik M, Bar V
IARC Sci Publ. 1982(41):659-64.
In earlier studies, it was found that the new antioxidant, MTDQ-DA ((6,6-methylene-bis)2,2-dimethyl-4-methane-sulphonic acid sodium salt-1,2-dihydroquinoline) (Patent No. 3172) prevented in vivo nitrosation and the acute hepatotoxicity of morpholine plus sodium nitrite in rats. The aim of the present experiments was to examine whether MTDQ-DA could decrease the frequency of tumours induced by simultaneous administration of morpholine and nitrite in the lung adenoma assay. Forty CFLP mice were used in each group and they were killed 8 months after treatment. In group A, treated with 1000 mg/kg morpholine i.g., and in Group B (untreated control) a similar frequency of lung adenomas could be observed (0.13 adenomas/mouse). After the combined i.g. treatment in Group C (MOR, 1000 mg/kg + nitrite, 125 mg/kg), the incidence of lung adenomas was found to be 16.58/mouse. A single dose of MTDQ-DA (500 mg/kg) added to the group C treatment reduced the lung adenoma frequency to 2.47/mouse (Group D). As MTDQ-DA shows neither toxic nor mutagenic effects and inhibits the in vivo nitrosation in both hepatotoxicity and lung adenoma assays, it may be considered to be a potential food additive.
在早期研究中发现，新型抗氧化剂MTDQ - DA（(6,6 - 亚甲基 - 双)2,2 - 二甲基 - 4 - 甲磺酸 - 1,2 - 二氢喹啉钠盐）（专利号3172）可防止大鼠体内亚硝化反应以及吗啡啉加亚硝酸钠所致的急性肝毒性。本实验的目的是在肺腺瘤试验中检测MTDQ - DA是否能降低同时给予吗啡啉和亚硝酸盐所诱发肿瘤的发生率。每组使用40只CFLP小鼠，治疗8个月后处死。A组腹腔注射1000 mg/kg吗啡啉，B组（未处理对照组）可观察到相似的肺腺瘤发生率（0.13个腺瘤/小鼠）。C组联合腹腔注射（吗啡啉，1000 mg/kg + 亚硝酸盐，125 mg/kg）后，肺腺瘤发生率为16.58个/小鼠。在C组治疗中添加单剂量的MTDQ - DA（500 mg/kg）可使肺腺瘤发生率降至2.47个/小鼠（D组）。由于MTDQ - DA既无毒性也无诱变作用，且在肝毒性和肺腺瘤试验中均能抑制体内亚硝化反应，因此可被视为一种潜在的食品添加剂。
